Literature DB >> 9330

Gastric mucosal lesions produced by intravenous infusion of aspirin in cats.

R Bugat, M R Thompson, D Aures, M I Grossman.   

Abstract

Aspirin was given by continuous intravenous infusion to 35 intact cats for 7 days in doses ranging from 25 to 200 mg kg-1 day-1. Gastric mucosal lesions occurred in 50 to 70% of the animals in the various dosage groups, including deep ulcers in 20%. All of the ulcers were in antral mucosa near its border with oxyntic mucosa. The incidence of lesions, including ulcers, showed no apparent relation to the dose of aspirin. With all but the highest dose, plasma salicylate levels were within or below what is regarded as the therapeutic range for man. Asprin, 100 mg kg-1 day-1, was given for 7 days to 4 cats with pouches containing all of the antral mucosa plus some oxyntic mucosa. One or more deep ulcers occurred in the antral mucosa of the pouches in each of these 4 cats. The electrical potential difference across the mucosa did not decrease, and net fluxes of hydrogen ions out of the pouch and of sodium ions into the pouch did not increase during the 7 days of aspirin administration despite the occurrence of ulcers in the pouches. It is concluded that intravenous aspirin, in doses giving plasma levels within or below the therapeutic range for man, causes gastric mucosal lesions including deep ulcers within 7 days in cats. These lesions occur without the changes in electrical potential difference and hydrogen and sodium fluxes that are regarded as characteristic of the "broken barrier."

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 9330

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  17 in total

Review 1.  Gastrointestinal cytoprotection by prostaglandins.

Authors:  T A Miller; E D Jacobson
Journal:  Gut       Date:  1979-01       Impact factor: 23.059

2.  Mitochondrial damage: a possible mechanism of the "topical" phase of NSAID induced injury to the rat intestine.

Authors:  S Somasundaram; S Rafi; J Hayllar; G Sigthorsson; M Jacob; A B Price; A Macpherson; T Mahmod; D Scott; J M Wrigglesworth; I Bjarnason
Journal:  Gut       Date:  1997-09       Impact factor: 23.059

3.  Drug-induced gastric mucosal injury.

Authors:  D Fromm
Journal:  World J Surg       Date:  1981-03       Impact factor: 3.352

4.  The gastric mucosal barrier. Component control.

Authors:  G L Kauffman
Journal:  Dig Dis Sci       Date:  1985-11       Impact factor: 3.199

5.  Nonsteroidal antiinflammatory drugs: effect on pyloric sphincter and duodenogastric reflux.

Authors:  J L Pantoja; C Defilippi; J E Valenzuela; A Csendes
Journal:  Dig Dis Sci       Date:  1979-03       Impact factor: 3.199

6.  Aspirin-induced gastric ulcers in cats. Prevention by prostacyclin.

Authors:  S J Konturek; T Radecki; T Brzozowski; I Piastucki; A Zmuda; A Dembińska-Kieć
Journal:  Dig Dis Sci       Date:  1981-11       Impact factor: 3.199

7.  The potentiation of taurocholate-induced rat gastric erosions following parenteral administration of cyclo-oxygenase inhibitors.

Authors:  B J Whittle
Journal:  Br J Pharmacol       Date:  1983-11       Impact factor: 8.739

Review 8.  Nabumetone: therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis.

Authors:  Thomas Hedner; Ola Samulesson; Peter Währborg; Hans Wadenvik; Kjell-Arne Ung; Anders Ekbom
Journal:  Drugs       Date:  2004       Impact factor: 9.546

9.  The effect of cigarette smoke on gastroduodenal mucosal endogenous prostacyclin level (experimental and clinical observations).

Authors:  G A Balint; V Varró
Journal:  Agents Actions       Date:  1986-11

10.  Changes in potential difference across the human buccal mucosa with buffered or unbuffered aspirin and salicylate.

Authors:  B J Whittle; K A Makki; J O'Grady
Journal:  Gut       Date:  1981-10       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.